Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice.
Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, Oddo S. · 2019
Read Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. by Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, Oddo S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6351836.txt.
Introduction
Belfiore and co-authors map Alzheimer's-like changes over time in a key mouse model. Their study appeared in Aging Cell. The 3xTg-AD mouse carries genes for the human disease. It has served labs for almost fifteen years. Reports on its timing of symptoms now conflict. The team rechecked the model at four ages.
Female mice were studied at 2, 6, 12, and 20 months. Amyloid plaques hit the rear hippocampus by six months. By twelve months all mice had hippocampal plaques. Cortical plaques, including in entorhinal cortex, appeared at twelve months. Tau marks showed in every hippocampus by then as well. Inflammation and memory were tracked in parallel. The timeline gives labs a firmer baseline for drug tests.
Catalog record
| CREATOR | Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, Oddo S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Temporal and regional progression of Alzheimer’s disease‐like pathology in 3xTg‐AD mice By Ramona Belfiore, Alexis Rodin, Eric Ferreira, Ramon Velazquez, Caterina Branca, Antonella Caccamo, Salvatore Oddo Published in: Aging Cell DOI: 10.1111/acel.12873 ABSTRACT Abstract Accumulation of amyloid‐β (Aβ) and fibrillary tangles, as well as neuroinflammation and memory loss, are hallmarks of Alzheimer’s disease (AD). After almost 15 years from their generation, 3xTg‐AD mice are still one of the most used transgenic models of AD. Converging evidence indicates that the phenotype of 3xTg‐AD mice has shifted over the years and contradicting reports about onset of pathology or cognitive deficits are apparent in the literature. Here, we assessed Aβ and tau load, neuroinflammation, and cognitive changes in 2‐, 6‐, 12‐, and 20‐month‐old female 3xTg‐AD and nontransgenic (NonTg) mice. We found that ~80% of the mice analyzed had Aβ plaques in the caudal hippocampus at 6 months of age, while 100% of them had Aβ plaques in the hippocampus at 12 months of age. Cortical Aβ plaques were first detected at 12 months of age, including in the entorhinal cortex. Phosphorylated Tau at Ser202/Thr205 and Ser422 was apparent in the hippocampus of 100% of 6‐month‐old mice, while only 50% of mice showed tau phosphorylation at Thr212/Ser214 at this age. Neuroinflammation was first evident in 6‐month‐old mice and increased as a function of age. These neuropathological changes were clearly associated with progressive cognitive decline, which was first apparent at 6 months of age and became significantly worse as the mice aged. These data indicate a consistent and predictable progression of the AD‐like pathology in female 3xTg‐AD mice, and will facilitate the design of future studies using these mice. INTRODUCTION Alzheimer’s disease (AD) is the most common neurodegenerative disease (Alzheimer’s Association, 2016). It is characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles (LaFerla & Oddo, 2005; Querfurth & LaFerla, 2010). The former are primarily made of a small peptide called amyloid‐β (Aβ), while the latter are made of hyperphosphorylated tau (Querfurth & LaFerla, 2010). Another hallmark of AD is brain inflammation, which manifests as intense reactivity of astrocytes and microglia, and increased levels of proinflammatory cytokines such as interleukin‐1β (IL1β), interleukin‐6 (IL6), and tumor necrosis factor‐α (TNFα; Heneka et al., 2015). Clinically, AD is first associated with episodic amnesia followed by significant deficits in semantic memory and procedural memory (Mormino et al., 2009). Additional clinical manifestations such as loss of judgment, problem‐solving impairment, depression, and sleep disorders are also frequently associated with early stages of the disease (Grontvedt et al., 2018). Familial AD, which represents a minority of AD cases, is due to mutations in one of three genes, presenilin (PS) 1 and 2 and the amyloid precursor protein (APP; Selkoe, 1997; Van Cauwenberghe, Broeckhoven, & Sleegers, 2016). In contrast, sporadic AD, which represents the vast majority of AD cases is of unknown etiology (Pluta, 2011; Zetterberg & Mattsson, 2014). For both familial and sporadic AD, aging is the major risk factor. Genetically, tau is not linked to AD, even though neurofibrillary tangles are a primary hallmark of AD. Mutations in the tau gene are associated with frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, and Pick’s disease (Tacik, Sanchez‐Contreras, Rademakers, Dickson, & Wszolek, 2016). Several animal models of AD have been generated and these include transgenic mice overexpressing different AD‐associated proteins (LaFerla & Green, 2012; Puzzo, Gulisano, Palmeri, & Arancio, 2015). Overall, mouse models of AD represent unique tools to understand underlying mechanisms of pathogenesis and have served to conduct numerous preclinical studies. In 2003, we generated a mouse model harboring three human mutant genes, APP, tau, and PS1 (Oddo, Caccamo, Kitazawa, Tseng, & LaFerla, 2003; Oddo, Caccamo, Shepherd, et al., 2003). These mice recapitulate specific aspects of AD including age‐dependent cognitive decline, accumulation of plaques and tangles, and age‐dependent inflammation (Janelsins et al., 2005; Oddo et al., 2008; Oddo, Caccamo, Kitazawa, et al., 2003; Oddo, Caccamo, Shepherd, et al., 2003). Over the last 15 years these mice have been widely used by investigators throughout the world. This widespread use of the mice has led to the generation of sublines, which present different onset and progression of AD‐like pathology, creating controversy and confusion in the field. Here we staged the AD‐like pathology in female 3xTg‐AD mice, to elucidate the spatial and temporal progression of soluble and insoluble Aβ, tau hyperphosphorylation, glial reactivity, and cognitive function. RESULTS 3xTg‐AD mice show an age‐dependent accumulation of plaques To assess the age‐dependent progression of Aβ pathology in female 3xTg‐AD mice, we immunostained sections from 2‐, 6‐, 12‐, and 20‐month‐old mice with an Aβ42‐specific antibody (n = 6/age group). We selected hippocampal sections from left hemibrains that were −3.80, −3.08, and −2.18 mm posterior to bregma, representing the caudal, medial, and rostral hippocampus, respectively. We found that extracellular Aβ plaques were absent in 2‐month‐old mice (Figure 1a–c) and first detected in the CA1/subiculum of 6‐month‐old mice (Figure 1d–f). At this age, five out of six mice analyzed had plaques in the caudal hippocampus, three out of six in the medial hippocampus and none in the rostral‐hippocampus. In contrast, 100% of the 12‐month‐old mice had plaques in all three hippocampal regions (Figure 1g–i). By 20 months of age, Aβ42 immunoreactivity was present throughout the hippocampus (Figure 1j–l). Quantitative analyses of the sections confirmed the age‐dependent progression of Aβ immunoreactivity in the caudal, medial, and rostral hippocampus (p < 0.0001; Figure 1m–o). To further assess the progression of Aβ pathology, we measured the amount of soluble and insoluble Aβ in the hippocampus of 3xTg‐AD mice by sandwich ELISA. One‐way ANOVA analysis showed that soluble Aβ40 levels were not statistically different among the four age groups (p = 0.0685; Figure 1p). In contrast, we found a statistically significant age‐dependent increase in insoluble Aβ40 (p = 0.0081; Figure 1r), and soluble and insoluble Aβ42 (p < 0.0001; Figure 1q,s). [Figure: Age‐dependent Aβ pathology in the hippocampus. (a–l) Representative microphotographs of hippocampal sections from 2‐, 6‐, 12‐, and 20‐month‐old 3xTg‐AD mice stained with an anti‐Aβ42‐specific antibody (n = 6/age group). As indicated, brain sections were selected at −3.80, −3.08, and −2.18 mm posterior to bregma. (m–o), Quantitative analysis of the anti‐Aβ42 immunoreactivity from the caudal (p < 0.0001, F 3,20 = 39.97), medial (p < 0.0001, F 3,20 = 32.6) and rostral (p < 0.0001, F 3,20 = 26.74) hippocampus. Post hoc analysis indicated that Aβ42 immunoreactivity in the caudal hippocampus (m) was significantly increased between 6 and 12 months of age (p < 0.0001) but not significantly increased between 12‐ and 20‐month‐old mice 3xTg‐AD (p = 0.0764). In contrast, a quantitative analysis of medial (n) and rostral (o) hippocampus showed significant differences among all the age‐groups (p < 0.001). (p–s), Sandwich ELISA measurements of soluble and insoluble Aβ40 and Aβ42 levels. The levels of soluble Aβ40 did not change as a function of age, whereas soluble Aβ42 levels were significantly different among the four age‐groups (p < 0.0001, F 3,31 = 19.74). Specifically, post hoc evaluations showed that the levels of soluble Aβ42 were significantly different between all the pairwise comparisons (p < 0.0001) except when comparing the 6‐ and 12‐month‐old mice. Insoluble Aβ40 changed as a function of age (p = 0.0081, F 3,31 = 4.699). Post hoc analyses